A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheimer's disease
Latest Information Update: 05 Mar 2026
At a glance
- Drugs Semaglutide (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 24 Feb 2026 Status changed from active, no longer recruiting to completed.
- 05 Jun 2024 Planned primary completion date changed from 11 Sep 2025 to 7 Aug 2024.
- 31 May 2024 Planned primary completion date changed from 16 May 2024 to 11 Sep 2025.